deCODE biostructures Announces Expansion of Collaboration with Replidyne to Include Fragments of Life™
News Nov 19, 2007
deCODE also announces the signing of an extension to the collaborative research agreement with Replidyne.
Under the terms of the extension, deCODE biostructures will continue to deliver ligand-bound structures and continue gene-to-structure collaborative research on additional proprietary targets.
The research fee and milestone-based collaboration provides Replidyne with access to deCODE's expertise in protein crystal structure determination and to deCODE's computational chemistry assets.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE